Skip to main content

Table 4 Association of Overall Survival and Recurrence Free Survival with Demographics and Disease Characteristics

From: Expression of the luteinizing hormone receptor (LHR) in ovarian cancer

FactorsNOverall Survival (Months)Recurrence Free Survival (Months)
Median (95% CI)p-value*Median (95% CI)p-value*
Overall23244.0 (39.7, 49.9) 26.3 (20.9, 38.0) 
Age at Diagnosis  < 0.001 < 0.001
 < 6013052.2 (45.0, 84.9)0.18^38.0 (22.3, 49.9)0.26^
 ≥6010236.8 (25.1, 41.8) 22.0 (15.3, 26.6) 
Pathologic Stage  < 0.001 < 0.001
 I/II68Not reached< 0.001^Not reached< 0.001^
 III/IV14038.0 (30.1, 41.8) 20.0 (16.6, 24.2) 
Silberberg’s Grade  < 0.001 < 0.001
 127Not reached0.23^Not reached0.060^
 2 or 320541.8 (37.9, 45.9) 24.2 (19.1, 29.9) 
Persistent Disease  < 0.001 < 0.001
 No14469.8 (52.2, 85.7)< 0.001^35.8 (20.9, 51.4)0.69^
 Yes8824.2 (15.3, 30.5) 24.2 (15.3, 30.5) 
LHR-I  0.28 0.27
 Negative/Weak/Moderate8051.2 (40.7, 65.9) 29.9 (19.0, 46.0) 
 Strong15241.9 (38.0, 45.3) 24.5 (19.6, 38.0) 
LHR-P  0.36 0.53
 ≤ 50%3450.3 (35.4, 74.3) 36.0 (19.0, 50.3) 
 >  50%19743.8 (39.2, 49.5) 24.6 (20.0, 38.0) 
  1. *p-value based on logrank test
  2. ^ p-value based on Wald test from Cox proportional model, adjusted by all other variables with p < 0.05 in univariate analysis